



# Amendments of EU regulation of micro-organisms used in plant protection products

SANTE E4

Domenico Deserio, Eric Liégeois

*ABIM 2021*

*20 October 2021*

# Regulations concerned

## Six texts applying on micro-organisms (MO)

- Amendments of:

- 1. data requirements for active substances (AS)*
- 2. data requirements for plant protection products (PPP)*
- 3. uniform principles for evaluation/authorisation of PPP*
- 4. Annex II to Regulation (EC) No 1107/2009 approval criteria of microbial AS*

- New:

- 5. Commission Communication on test methods and guidance documents for AS*
- 6. Commission Communication on test methods and guidance documents for PPP*


# 2030 Farm to Fork Targets



Reduce by 50% the overall use and risk of **chemical pesticides** and reduce use by 50% of more hazardous **pesticides**



Reduce **nutrient losses** by at least 50% while ensuring no deterioration in soil fertility; this will reduce use of **fertilisers** by at least 20 %



Reduce sales of **antimicrobials** for farmed animals and in aquaculture by 50%



Achieve at least 25% of the EU's agricultural land under **organic farming** and a significant increase in **organic aquaculture**


# Principles of the revision

- ❑ New scientific approaches:
  - ✓ MO are intrinsically different from chemicals, so they deserve a specific approach!
  - ✓ We know more about MO: science evolved, technology offers new opportunity
  - ✓ AIR program: more “fresh” experience with “real-life” dossiers
  - ✓ Weight of evidence
  
- ❑ Be good at the first time (dossiers’ quality)
  - ✓ “Need-to-know” approach (i.e. which questions are we trying to answer?)
  - ✓ More emphasis on request to justify missing data
  
- ❑ Tiered-based approach (mandatory and conditional requirements)

# Revision of concerned Regulations

## Milestones


The Biopesticides Working Group!



1: Standing Committee Plant, Animal, Food and Feed  
2: interservice consultation

# Biological properties

- **Central role** in data requirements, information for weight of evidence (**WoE**) **approach** – connection with other sections



# Biological properties

❑ e.g. “Growth requirement” on biological properties to support WoE in human tox

❑ Clear separation between:

✓ presence of antimicrobial resistance (AMR)

genotype,

✓ possibility of AMR to be transferred, and


✓ treatment options (*i.e.* this in human tox. section).

- Guidance document
- Only relevant antimicrobial agents (e.g. Regulation (EC) No 2019/6\* or WHO definition)

# Biological properties

Identification of metabolites of concern – connection with other sections


## Identification of metabolites of concern





# Biological properties

## Identification of metabolites of concern – relevant ones



# Effects on human health

## Human **toxicity** of metabolites of concern

1- Were metabolites of concern identified (human dietary and non-dietary exposure)?

- Possible **identification** in **biological properties**



2- Setting toxicological reference values

- Is it possible to **set tox reference values** based on data available in biological properties?



3- Data generation

- Possibly required on a case-by-case basis (reference to **Part A** of data requirements for chemical AS)



# Effects on human health

## Human **pathogenicity** of micro-organisms


### 1- Weight of evidence approach

- **Biological properties** (e.g. occurrence, history of use, MoA, host specificity, growth requirements, relationship with known pathogens, infectiveness)
- **Medical data** (e.g. surveillance, direct observation)
- Others (e.g. peer-reviewed **literature**, **Qualified Presumption of Safety**)



### 2- Pathogenicity and infectivity studies (new data generation)

- Acute oral, and/or
- Acute intratracheal/ intranasal, and/or
- Intravenous/Intraperitoneal or subcutaneous test



### 3- Specific pathogenicity and infectivity studies (new data generation)

- If WoE and Pathogenicity and infectivity studies require further investigation



# Effects on human health

Only toxicity studies (no pathogenicity)

## 1- Weight of evidence approach

- Physical, chemical, technical properties, data on application, others (e.g. CLP calculation rules)

## 2- Toxicity studies

- Acute oral, and/or
- Acute dermal, and/or
- Acute inhalation
- Skin irritation
- Eye irritation
- Skin sensitisation

## 3- Additional studies

- If further investigation as required

No  
more  
data

No  
more  
data


# Residues Fate & Behaviour

## 1- Extrapolation of existing data

- **Extrapolation** for PPP possible by using data submitted for AS?

## 2- Data generation

- Same dataset described in Reg. 283/2013



# Approval criteria and uniform principles

## □ Annex II to Reg. 1107/2009, approval criteria:

- No new criteria, but specification for micro-organisms on Art 4 Reg 1107/2009 (e.g. human pathogenicity, AMR transfer)
- Low risk criteria

## □ Reg. 546/2011 (Uniform Principles) evaluation + decision-making for PPP:

- Adaptation to new data requirements

# To sum-up

- ❑ Need-to-know approach: no unnecessary studies, maximal use of available information regarding biology
- ❑ Tiered-based approach: if data/results identify a concern, assessment continues, otherwise 'stop' (!)
- ❑ Key techniques (e.g. genomics) helpful for waiving possible questions on AMR, metabolites, etc...
- ❑ Have your say: [https://ec.europa.eu/food/horizontal-topics/consultations-and-feedback\\_en#consultations](https://ec.europa.eu/food/horizontal-topics/consultations-and-feedback_en#consultations)

# Keep in touch



[ec.europa.eu/](https://ec.europa.eu/)



[europa.eu/](https://europa.eu/)



[@EU\\_Commission](https://twitter.com/EU_Commission)



[@EuropeanCommission](https://www.facebook.com/EuropeanCommission)



[European Commission](https://www.linkedin.com/company/european-commission)



[europeancommission](https://www.instagram.com/europeancommission)



[@EuropeanCommission](https://www.medium.com/@EuropeanCommission)



[EUTube](https://www.youtube.com/EUTube)



[EU Spotify](https://www.spotify.com/eu)



# Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: **element concerned**, source: **e.g. Fotolia.com**; Slide xx: **element concerned**, source: **e.g. iStock.com**

